Corline Biomedical AB OMXSTO:CLBIO:
Q1 2026 NET SALES AMOUNT TO 4,291 KSEK
Q1 2026 RESULT AFTER FINANCIAL ITEMS AT -2,501 KSEK
Corline Biomedical Q1 Result After Financial Items At SEK -2.5 Mln
Earlier from Corline Biomedical Ab
- Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence
- CLBIO: FDA approval, US launch, and a major 10-year deal drove a pivotal commercial breakthrough
- Corline Flags Share Issue Raising About SEK 9.24 Mln
- CLBIO: Breakthrough quarter with FDA approval, long-term deal, and capital raise set stage for growth